CureVac CEO on IPO Pricing, Covid-19 Vaccine, Partners

The transcript discusses stock pricing and market demand, highlighting a significant spread in stock opening prices. It covers a partnership with GSK for vaccine development, focusing on mRNA technology and clinical trials. The conversation also addresses funding, government involvement, and the global race to develop a COVID-19 vaccine, emphasizing the importance of safety, efficacy, and manufacturing capabilities.

In what ways does the text suggest that the pandemic has accelerated vaccine development?

How does the text describe the relationship between vaccine producers and government entities?

What considerations are mentioned regarding the effectiveness and safety of the vaccine?